Search Browse Earnings

C4 Therapeutics, Inc. — SlamSEC

C4 Therapeutics, Inc.

Nasdaq:CCCC

Biological Products, (No Diagnostic Substances)·WATERTOWN, MA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$35.6M

+71.4% YoY

FY 2025

Adj. EBITDA

-$117.8M

-331.0% margin

FY 2025

Net Income

-$105.3M

-296.0% margin

FY 2025

EPS (Diluted)

-$1.52

FY 2025

Stock Price

$2.99

-3.9%

2026-03-11

52W Range

$1.08 – $3.82

P/E Ratio

-2.0x

Market Cap

$291.8M

Cash

$55.5M

FY 2025

Total Debt

$9.2M

FY 2023

Net Cash

$46.3M

FY 2023

Enterprise Value

$245.5M

Debt / EBITDA

0.4x

FY 2025

EV / EBITDA

-2.1x

Employees

—

CEO

Hirsch Andrew

CFO

Adams Kendra